BACKGROUND: Serum prostate specific antigen (PSA) may be elevated in otherwise healthy men; systemic inflammation has been associated with cancer. The study of systemic inflammatory markers in men without clinical prostate disease, but with elevated PSA may characterize the subgroup of men at higher risk for subsequent prostate cancer. METHODS: We investigated the associations between systemic inflammatory markers and serum PSA in 3,164 healthy men without prostatic disease, aged >40 years, from the 2001 to 2008 U.S. National Health and Nutrition Examination Survey (NHANES). Serum total PSA levels and concentrations of serum C-reactive protein (CRP) and plasma fibrinogen, neutrophil count, lymphocyte count, and platelet count were recorded. Neutrophil-lymphocyte ratio (NLR) ratio and platelet-lymphocyte (PLR) ratio were calculated. PSA elevation was defined as levels equal or greater than 4 ng/ml. RESULTS: Elevated serum PSA (194 men, 6.1% of the total), was significantly associated with plasma fibrinogen (ORmultiv = 1.88; 95% CI, 1.09-3.25), and NLR (ORmultiv = 1.14; 95% CI, 1.03-1.26), after adjustment for age, smoking, body mass index, education, race, co-morbidities, and use of medications. CONCLUSIONS: Markers of systemic inflammation were associated with elevated PSA in men without known prostatic disease. Future studies are needed to examine these markers' relationship with prostate cancer occurrence and progression.
BACKGROUND: Serum prostate specific antigen (PSA) may be elevated in otherwise healthy men; systemic inflammation has been associated with cancer. The study of systemic inflammatory markers in men without clinical prostate disease, but with elevated PSA may characterize the subgroup of men at higher risk for subsequent prostate cancer. METHODS: We investigated the associations between systemic inflammatory markers and serum PSA in 3,164 healthy men without prostatic disease, aged >40 years, from the 2001 to 2008 U.S. National Health and Nutrition Examination Survey (NHANES). Serum total PSA levels and concentrations of serum C-reactive protein (CRP) and plasma fibrinogen, neutrophil count, lymphocyte count, and platelet count were recorded. Neutrophil-lymphocyte ratio (NLR) ratio and platelet-lymphocyte (PLR) ratio were calculated. PSA elevation was defined as levels equal or greater than 4 ng/ml. RESULTS: Elevated serum PSA (194 men, 6.1% of the total), was significantly associated with plasma fibrinogen (ORmultiv = 1.88; 95% CI, 1.09-3.25), and NLR (ORmultiv = 1.14; 95% CI, 1.03-1.26), after adjustment for age, smoking, body mass index, education, race, co-morbidities, and use of medications. CONCLUSIONS: Markers of systemic inflammation were associated with elevated PSA in men without known prostatic disease. Future studies are needed to examine these markers' relationship with prostate cancer occurrence and progression.
Authors: K Shafique; M J Proctor; D C McMillan; K Qureshi; H Leung; D S Morrison Journal: Prostate Cancer Prostatic Dis Date: 2011-11-29 Impact factor: 5.554
Authors: Tytti H Yli-Hemminki; Marita Laurila; Anssi Auvinen; Liisa Määttänen; Heini Huhtala; Teuvo L J Tammela; Paula M Kujala Journal: BJU Int Date: 2013-06-07 Impact factor: 5.588
Authors: Graeme J K Guthrie; Kellie A Charles; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Stephen J Clarke Journal: Crit Rev Oncol Hematol Date: 2013-04-17 Impact factor: 6.312
Authors: Adetunji T Toriola; Jari A Laukkanen; Sudhir Kurl; Kristiina Nyyssönen; Kimmo Ronkainen; Jussi Kauhanen Journal: Int J Cancer Date: 2013-07-13 Impact factor: 7.396
Authors: T Kantola; K Klintrup; J P Väyrynen; J Vornanen; R Bloigu; T Karhu; K-H Herzig; J Näpänkangas; J Mäkelä; T J Karttunen; A Tuomisto; M J Mäkinen Journal: Br J Cancer Date: 2012-10-11 Impact factor: 7.640
Authors: Jacob A Burns; Adam B Weiner; William J Catalona; Eric V Li; Edward M Schaeffer; Stephen B Hanauer; Scott Strong; James Burns; Maha H A Hussain; Shilajit D Kundu Journal: Eur Urol Date: 2018-12-04 Impact factor: 20.096
Authors: Y Wang; W Yin; Z Wang; J Huang; J Pan; Y Zhu; F Xu; X Shao; J Sha; Y Cai; Q Liu; B Dong; W Xue; Y Huang Journal: Prostate Cancer Prostatic Dis Date: 2016-03-08 Impact factor: 5.554